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OBJECTIVES The aim of this study was to evaluate current American College of Cardiology/American
Heart Association (ACC/AHA) hospital percutaneous coronary intervention (PCI) volume
minimum recommendations.
BACKGROUND In order to reduce procedure-associated mortality, ACC/AHA guidelines recommend that
hospitals offering PCIs perform at least 400 PCIs annually. It is unclear whether this volume
standard applies to current practice.
METHODS We conducted a retrospective analysis of the Agency for Healthcare Research and Quality’s
Nationwide In-patient Sample hospital discharge database to evaluate in-hospital mortality
among patients (n  362,748) who underwent PCI between 1998 and 2000 at low (5 to 199
cases/year), medium (200 to 399 cases/year), high (400 to 999 cases/year), and very high
(1,000 cases or more/year) PCI volume hospitals.
RESULTS Crude in-hospital mortality rates were 2.56% in low-volume hospitals, 1.83% in medium-
volume hospitals, 1.64% in high-volume hospitals, and 1.36% in very high-volume hospitals
(p  0.001 for trend). Compared with patients treated in high-volume hospitals (odds ratio
[OR] 1.00, referent), patients treated in low-volume hospitals remained at increased risk for
mortality after adjustment for patient characteristics (OR 1.21, 95% confidence interval [CI]
1.06 to 1.28). However, patients treated in medium-volume hospitals (OR 1.02, 95% CI 0.92
to 1.14) and patients treated in very high-volume hospitals (OR 0.94, 95% CI 0.85 to 1.03)
had a comparable risk of mortality. Findings were similar when high- and very high-volume
hospitals were pooled together.
CONCLUSIONS We found no evidence of higher in-hospital mortality in patients undergoing PCI at
medium-volume hospitals compared with patients treated at hospitals with annual PCI
volumes of 400 cases of more, suggesting current ACC/AHA PCI hospital volume
minimums may merit reevaluation. (J Am Coll Cardiol 2004;43:1755–62) © 2004 by the
American College of Cardiology FoundationA
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rhere is growing interest in the use of procedure volumes as
means of identifying hospital quality of care (1). At the
orefront of this effort is the Leapfrog Group, a collection of
arge health care purchasers that recommends, as part of
See page 1763
broader safety initiative, using hospital volume as an
xplicit criterion when contracting for selected procedures
2). Matching current American College of Cardiology/
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Manuscript received May 20, 2003; revised manuscript received September 15,003, accepted September 23, 2003.merican Heart Association (ACC/AHA) percutaneous
oronary intervention (PCI) clinical practice guidelines (3),
eapfrog has established a minimum institutional volume
equirement of 400 cases per year for hospitals offering PCI
2,4–6). This volume threshold is based primarily on
tudies of PCI use in the late 1980s and early 1990s that
dentified an increased mortality risk for patients treated at
ospitals with annual PCI volumes of fewer than 400 cases
7–13). In the past 5 to 10 years, however, there have been
otable changes in PCI practice, including the adoption and
idespread use of stents, new pharmacologic therapies such
s glycoprotein IIb/IIIa inhibitors, and an increase in the
verall use of PCI (14,15). These changes in technology and
ractice patterns raise the possibility that the currently
ecommended hospital PCI volume threshold of 400 cases
ay no longer be appropriate. However, no published study,
o our knowledge, has assessed national PCI practice pat-
erns after 1997.
To address this issue, we evaluated the association be-
ween hospital PCI volume and mortality in a contempo-
ary, national cohort of patients who underwent PCI be-
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Hospital PCI Volume May 19, 2004:1755–62ween 1998 and 2000. We sought to determine specifically
hether patients treated at hospitals that conducted fewer
CIs than the current annual PCI volume minimum had
igher mortality rates than patients treated at higher volume
ospitals. This is particularly important, considering pur-
hasers’ proposed efforts to limit PCI services to hospitals
eeting annual PCI volume criteria (2).
ETHODS
ational In-patient Sample. We utilized data from the
ational In-patient Sample (NIS), a hospital discharge
atabase created as part of the Agency for Healthcare
esearch and Quality’s (AHRQ) Health Care Utilization
roject (16). The NIS is the largest publicly available
ll-payer inpatient database in the U.S., consisting of
dministrative billing records for all hospitalizations that
ccurred in a national, randomly selected set of acute care,
on-governmental hospitals (17). For the year 2000, the
IS contains information on more than 7.5 million dis-
harges occurring at nearly 1,000 hospitals in 28 states (18),
r approximately 20% of all community hospitals in the
.S. The AHRQ compiles a public use, de-identified,
ospitalization-level data set containing information on
rimary and secondary diagnoses, demographic characteris-
ics, procedure use, length of stay, payer, total charges, and
dmission and discharge status from data collected by
articipating state health data organizations (16). For the
urposes of our study, we pooled data from 1998, 1999, and
000, the three most recent years of the NIS.
tudy sample. We restricted our analysis to hospitaliza-
ions in which a patient had a primary or secondary
rocedure code indicating a PCI (International Classifica-
ion of Diseases-9th Edition-Clinical Modification [ICD-
] procedure codes 36.00 to 36.06 and 36.09). Of the 21
illion patient records in the 1998, 1999, and 2000 NIS,
63,155 indicated that a PCI occurred during hospitaliza-
ion. From this set, we excluded patients under the age of 18
n  153) and neonatal or obstetric admissions (n  23) in
rder to restrict our evaluation to the use of PCI in a typical
dult population. Records missing data for gender (n 14),
Abbreviations and Acronyms
ACC/AHA  American College of Cardiology/
American Heart Association
AHRQ  Agency for Healthcare Research and
Quality
CI  confidence interval
ICD-9-CM  International Classification of Diseases-
9th Revision-Clinical Modification
MI  myocardial infarction
NIS  Nationwide In-patient Sample
OR  odds ratio
PCI  percutaneous coronary intervention
SMR  standard mortality ratioge (n  11), or mortality during hospitalization (n  26) vere also excluded. Of the 362,928 remaining records, we
xcluded records of patients (n  180) treated at hospitals
ith fewer than five PCIs coded in any year in order to limit
he influence of administrative data coding errors (12,19–
1). The final study cohort consisted of 362,748 admissions
t 457 hospitals.
ospital PCI volume groups. To assess the validity of the
nnual hospital PCI volume threshold of 400 cases recom-
ended by current ACC/AHA PCI guidelines (3) and by
he Leapfrog Group (2), we divided our cohort into four
roups. Hospitals with fewer than 400 annual cases were
ivided into those with 5 to 199 cases (hereafter referred to
s low-volume) and 200 to 399 cases (medium-volume) to
istinguish true low providers from mid-volume providers
hat approached the volume requirement (8,10,12,13,21–
6). Hospitals with at least 400 annual cases were divided
nto those with 400 to 999 cases (high-volume) and those
ith 1,000 cases or more (very high-volume) to distinguish
ospitals with sufficient PCI capability from centers with
edicated, high-volume PCI services (11,27).
tatistical analysis. Patient characteristics, including de-
ographics, admission type, comorbidities, and payer, were
ompared across the four hospital PCI volume groups using
lobal chi-square analyses for categorical variables, and
nalyses of variance for continuous variables.
The principal study outcome was in-hospital mortality.
e compared crude rates of in-hospital mortality across all
our hospital PCI volume groups using global chi-square
nd test of trend analyses. Unadjusted logistic regression
nalyses were used to evaluate the consistency of the
ssociation between hospital PCI volume and mortality
hen stratifying by gender, age, single-vessel versus
ultiple-vessel PCI, history of diabetes, myocardial infarc-
ion (MI) during admission, admission type, admission
ource, and year.
Multivariable logistic regressions employing generalized
stimating equations were conducted to assess the indepen-
ent association of hospital PCI volume and patient mor-
ality accounting for the clustered nature of the study sample
admissions within year-specific hospital clusters). Patient
haracteristics incorporated in the multivariable model were
dentified on the basis of a review of prior studies of PCI
olume and outcomes and clinical judgment. These vari-
bles included gender, admission source, urgency of admis-
ion, age, year, multiple vessel PCI (ICD-9 procedure code
6.05), stent, MI as a principal diagnosis (ICD-9 diagnosis
ode 410), MI as a secondary diagnosis, any other non-MI
oronary disease diagnosis (ICD-9 diagnosis codes 411 to
14), diabetes (ICD-9 diagnosis code 250), chronic ob-
tructive pulmonary disease (ICD-9 diagnosis codes 490 to
96), hypertension (ICD-9 diagnosis codes 401 to 405), and
enal dysfunction (ICD-9 diagnosis codes 580 to 586).
ecause we specifically sought to examine the value of the
urrent hospital PCI volume minimum of 400 cases, mor-
ality rates and risks among patients treated in medium-
olume (200 to 399 cases) and high-volume (400 to 999
c
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May 19, 2004:1755–62 Hospital PCI Volumeases) hospitals were compared directly. We also compared
he experience of patients treated at medium-volume hos-
itals (200 to 399 cases) with that of patients treated at the
ombined group of high- and very high-volume hospitals
400 cases and higher).
Standardized mortality ratios (SMRs) were calculated for
ach hospital by dividing the hospital’s observed mortality
ate by its expected mortality rate, as predicted by the
ovariates employed in our multivariable model (excluding
ospital PCI volume). Hospitals with SMRs of 1.0 had
etter outcomes than expected, while hospitals with SMRs
1.0 had worse outcomes than expected. Box and whisker
lots were used to present the distribution of hospital SMRs
or each of the four hospital PCI volume groups.
This study was approved by the University of Pennsylva-
ia Institutional Review Board. All analyses were conducted
sing the SAS 8.2 (SAS Institute Inc., Cary, North Caro-
ina) and Stata 7.0 (Stata Corp., College Station, Texas)
oftware packages.
ESULTS
atient characteristics. Of the 362,748 admissions in the
tudy cohort, 14,575 (4%) were treated at low-volume
ospitals, 42,054 (12%) at medium-volume hospitals,
52,500 (42%) at high-volume hospitals, and 153,619
42%) at very high-volume hospitals (Table 1). Patients
reated at lower volume hospitals were on average younger,
nd larger proportions were female, non-white, and had
edicaid insurance. Lower volume hospitals treated higher
isk cases, on average, as reflected by the larger proportion of
atients with MI and smaller proportions of elective admis-
ions and patients who arrived by interhospital transfer. The
roportions of procedures utilizing stents and involving
ultiple vessels were greater across successively larger hos-
ital PCI volume groups. The proportions of patients with
ypertension, diabetes, and chronic obstructive pulmonary
isease were comparable across the four hospital PCI
olume groups.
CI volume and crude in-hospital mortality. Crude in-
ospital morality rates were associated with PCI volume,
anging from 2.56% for patients treated in low-volume
ospitals to 1.36% for patients treated in very high-volume
ospitals (p 0.001 for trend). Patients treated in medium-
olume hospitals had higher in-hospital mortality rates than
atients treated in high-volume hospitals (1.83% vs. 1.64%,
 0.008) (Table 2).
The association between hospital PCI volume category
nd crude in-hospital mortality varied by patient age;
ortality rates were markedly higher for patients age 75
ears and older treated in low-volume hospitals (p  0.007
or interaction). Differences in in-hospital mortality across
ospital volume groups were greater for patients with an MI
low-volume hospital 4.52% vs. very high-volume hospital
.35%) than for patients who did not have an MI (low-
olume hospitals 0.79% vs. very high-volume hospital c.41%; p  0.04 for interaction). Crude mortality for
atients at medium-, high-, and very high-volume hospitals
ombined was 1.54%, which was significantly lower than the
ortality for patients at low-volume hospitals excluding
enters with 100 (2.44%, p  0.001), 50 (2.44%, p 
.001), and 25 (2.48%, p  0.001) cases. The crude
ssociation of hospital PCI volume and mortality was
therwise consistent across patient gender, diabetes status,
ultiple-vessel PCI, arrival by transfer, type of admission,
nd year. No significant interactions were observed when
ortality rates were compared only between patients treated
t medium-volume and high-volume hospitals (Table 2).
djusted analysis. Patients treated at low-volume hospi-
als remained at increased risk for in-hospital mortality
odds ratio [OR] 1.21, 95% confidence interval [CI] 1.06 to
.38) after multivariable adjustment compared with patients
reated in high-volume hospitals (referent) (Table 3). How-
ver, patients treated at medium-volume hospitals (OR
.02, 95% CI 0.92 to 1.14) and patients treated at very
igh-volume hospitals (OR 0.94, 95% CI 0.85 to 1.03) had
mortality risk similar to patients treated in high-volume
ospitals after multivariable adjustment. In-hospital mor-
ality risks were also similar when comparing patients
reated in medium-volume hospitals with patients treated at
ery high-volume hospitals (p  0.29 for test of equality of
dds ratios). Patients treated in medium-volume hospitals
ontinued to have a mortality risk comparable to that of
atients treated at high- and very high-volume hospitals
hen those hospitals were pooled together (OR 1.05, 95%
I 0.95 to 1.16). Findings were unchanged when analyses
ere repeated evaluating interactions for patient gender,
ge, number of vessels, acute MI admission, history of
iabetes, type and urgency of admission, and year.
The box and whisker plot showed large variation in the
istribution of hospital SMRs within and across the four
ospital PCI volume groups (Fig. 1). The median hospital
MR ranged from 0.99 for low-volume hospitals down to
.92 for high-volume hospitals. A sizeable proportion of
ospitals in each PCI volume group had SMRs above 1.0,
ndicating higher mortality rates than predicted.
ISCUSSION
ur evaluation of patients undergoing PCI in a national,
andom sample of hospitals between 1998 and 2000 dem-
nstrates that patients treated at medium-volume hospitals
200 to 399 cases annually) and patients treated at hospitals
ith 400 or more PCI cases had statistically comparable
ortality rates. These findings challenge earlier reports of
oorer outcomes for patients undergoing PCI at middle-
olume centers (7–13,19,21,24,26). Our results further sug-
est that efforts by the Leapfrog Group advocating a
inimum annual hospital PCI volume of 400 cases are
nlikely to achieve sizable reductions in PCI-related patient
ortality (4–6). Moreover, our findings do not supporturrent ACC/AHA PCI clinical practice guidelines recom-
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Hospital PCI Volume May 19, 2004:1755–62ending hospitals maintain a minimum annual PCI volume
f 400 cases (3).
Our findings should not be interpreted as evidence that
here is no association between hospital PCI volume and
ortality. Indeed, we found that patients treated at hospi-
als that performed fewer than 200 PCI procedures annually
able 1. Patient Characteristics Across Hospital PCI Volume Gr
Characteristics Overall (<
Patients 362,748 14
of Patients 100.0
Hospitals 457
of Hospitals 100.0
Hospital-year groups* 659
of Hospital-year groups* 100.0
edian age 65
ge
65 yrs 49.1
65–74 yrs 29.0
75 yrs of age and older 21.9
ale 65.5
ace
White 64.3
Black 4.4
Other 6.8
Race not reported/missing 24.5
rimary payer
Medicare 48.5
Medicaid 3.8
Private 41.7
Other/missing 5.9
iabetes 24.4
ypertension 52.6
hronic obstructive pulmonary disease 11.2
enal disease 2.5
oronary disease
Myocardial infarction as primary diagnosis 31.4
Myocardial infarction as secondary diagnosis 4.7
Other coronary artery disease diagnosis 60.4
No coronary artery disease diagnosis 3.5
dmission type
Emergency 32.6
Urgent 25.6
Elective 29.9
Other/missing 11.3
rrived by interhospital transfer
Yes 17.8
No 78.3
Unknown 3.9
ultiple vessel procedure 14.3
tent employed 81.7
oronary bypass surgery-capable hospital 98.8
ear
1998 29.6
1999 32.0
2000 38.4
nless noted otherwise, findings are expressed as percentages. Percentages may no
ontributed data in each year of the Nationwide In-patient Sample (NIS). A hospital
hree hospital-year groups to the analysis.
PCI  percutaneous coronary intervention.ad a higher risk of mortality than patients at hospitals in any other PCI volume group. At the same time, we noted
ubstantial heterogeneity in hospital SMRs within each of
he hospital PCI volume groups, and failed to find a
tatistically significant difference in mortality risks among
atients treated in medium, high, or very high PCI volume
ospitals. Given that we evaluated over 360,000 admissions
Hospital Annual PCI Volume Groups
(Cases/Year Volume Cut Points)
Overall p)
Medium
(200–399)
High
(400–999)
Very High
(>1,000)
42,054 152,500 153,619 —
0 11.6 42.0 42.3 —
98 171 66 —
7 21.4 37.4 14.4 —
140 251 99 —
6 21.2 38.1 15.0 —
64 65 65 0.001
0.001
1 50.5 49.7 47.9
5 28.1 28.7 29.8
4 21.4 21.6 22.8
7 65.4 65.7 65.6 0.001
0.001
4 61.0 67.6 63.6
1 5.2 4.4 4.1
9 8.8 7.4 5.2
6 25 20.6 27.1
0.001
6 45.9 47.0 50.9
1 4.3 4.2 3.0
7 41.6 42.5 41.2
6 8.2 6.2 4.9
3 24.2 23.7 25.0 0.001
0 51.8 51.3 54.4 0.001
8 11.8 11.3 10.8 0.001
9 2.6 2.3 2.5 0.001
0.001
5 36.4 33.2 27.3
9 5.0 4.4 5.0
7 55.2 59.2 64.1
0 3.4 3.1 3.7
0.001
6 32.4 32.7 31.3
3 26.9 26.1 27.4
7 22.9 28.3 37.3
4 17.8 12.9 4.1
0.001
8 10.4 16.9 21.6
2 86.4 79.1 74.5
0 3.2 4.0 3.9
4 13.2 13.7 15.4 0.001
8 80.8 81.5 82.8 0.001
8 98.1 100.0 100.0 0.001
0.001
4 33.1 33.7 24.2
9 32.4 32.4 31.6
7 34.6 33.9 44.2
100 due to rounding. *Hospital-year groups refer to the number of hospitals that
ating in the NIS over the three-year period would be considered to have contributedoups
Low
200
,575
4.
122
26.
169
25.
64
51.
27.
21.
62.
46.
5.
10.
37.
45.
8.
38.
7.
25.
51.
11.
2.
42.
4.
47.
5.
45.
21.
15.
17.
7.
86.
6.
11.
74.
75.
34.
29.
35.
t total
participt 457 hospitals throughout the U.S. over a three-year
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May 19, 2004:1755–62 Hospital PCI Volumeeriod, we believe this analysis, unlike previous reports of a
eutral volume-outcome association (22,28), was sufficiently
owered to detect even a modest difference between hospital
CI volume groups (3). If our analysis failed to detect a
olume-mortality association, the magnitude of any such
ffect would have been so small as to be virtually meaning-
ess from either a clinical or policy perspective. Finally, the
imilarity in mortality rates between medium, high, and very
igh hospitals across a variety of clinical strata suggests these
esults are robust and not limited to selected patient groups.
There are several potential explanations for the compa-
able mortality rates among patients treated in medium,
igh, and very high PCI volume hospitals. Percutaneous
oronary intervention technology has changed markedly
ince the first studies of hospital PCI volume and outcomes
14,29,30). Although the adoption of coronary stents during
he mid-1990s improved patient outcomes (13,14,30–32),
revious studies indicated that patients undergoing PCIs
nvolving stents at higher volume centers continued to have
able 2. Crude In-Hospital Mortality Rates
Hospital Annu
All
Hospitals
Low
(<200)
Medium
(200–399)
High
(400–999
verall 1.58 2.56 1.83 1.64
ender
Male 1.27 2.15 1.50 1.31
Female 2.17 3.24 2.46 2.27
ge
65 yrs 0.72 1.37 0.93 0.76
65–74 yrs 1.64 2.27 2.09 1.76
75 yrs and older 3.42 5.78 3.62 3.52
essels
Single 1.58 2.59 1.79 1.63
Multiple 1.56 2.29 2.13 1.70
iabetes
Yes 1.57 2.61 1.88 1.70
No 1.58 2.54 1.81 1.62
cute myocardial
infarction
Yes (primary or
secondary)
3.54 4.52 3.61 3.57
No 0.47 0.79 0.57 0.48
dmission
Arrived by transfer 1.83 2.20 1.93 1.98
Direct admission 1.51 2.49 1.77 1.57
Unknown 1.91 3.98 3.18 1.61
ype of admission
Emergency 2.38 3.32 2.50 2.46
Urgent 1.56 2.26 1.79 1.53
Elective 0.72 1.26 0.75 0.78
Other/missing 1.71 2.10 2.06 1.70
ear
1998 1.69 2.37 1.92 1.71
1999 1.62 2.82 1.75 1.68
2000 1.46 2.52 1.82 1.55
nteraction p values were obtained from a logistic regression model of in-hospital mo
ategory, the strata of interest, and their interaction. The p values were obtained from
o 0.ower mortality rates than patients undergoing PCIs involv- ang stents at lower volume centers (13,19,23,32,33). How-
ver, these studies evaluated procedure use before 1998.
tents may have attenuated the hospital PCI volume-
ortality difference between medium-, high-, and very
igh-volume hospitals in subsequent years as additional
perators were trained in their use, operators became more
xperienced, and newer stent designs were incorporated into
ractice. In addition, the increased use of new adjunctive
harmacologic therapies in the late 1990s, including glyco-
rotein IIb/IIIa receptor inhibitors (34) may have reduced
he mortality difference between medium, high, and very
igh PCI volume hospitals. As in the case of stents, the full
eneficial effect of these therapies may not have been
bserved in previous studies (13,19,23,32,33).
Technological improvements in PCI have been accom-
anied by significant changes in PCI practice patterns in the
ast decade (14,15,24,26,29). The substantial increase in
he number of PCIs performed reflects a rise not only in the
umber of providers performing PCIs (i.e., diffusion), but
I Volume Groups (Cases/Year Volume Cut Points)
Very High
(>1,000)
Trend
p
Medium vs.
High p
Overall
Interaction p
Medium vs.
High
Interaction p
1.36 0.001 0.008 – –
0.649 0.580
1.08 0.001 0.020
1.68 0.001 0.171
0.007 0.168
0.72 0.001 0.012
1.36 0.001 0.020
3.05 0.001 0.649
0.142 0.225
1.37 0.001 0.045
1.26 0.001 0.031
0.242 0.902
1.26 0.001 0.224
1.39 0.001 0.018
0.040 0.164
3.35 0.001 0.770
0.41 0.001 0.073
0.091 0.142
1.70 0.057 0.837
1.24 0.001 0.009
1.61 0.001 0.001
0.725 0.459
2.13 0.001 0.773
1.47 0.001 0.048
0.64 0.001 0.732
1.18 0.001 0.001
0.681 0.705
1.50 0.001 0.087
1.41 0.001 0.555
1.24 0.001 0.021
containing terms for each hospital percutaneous coronary intervention (PCI) volume
iple partial F-tests assessing whether coefficients for the interaction term were equalal PC
)
rtality
multlso in the total number of procedures ever performed by
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Hospital PCI Volume May 19, 2004:1755–62ach provider (i.e., accumulated experience) (26). This
umulative gain in provider experience may explain why
ortality rates are now similar across medium, high, and
ery high PCI volume hospital groups. Additionally, the
linical threshold for PCI use has changed over time
14,24,30). To the extent that increases in PCI volume have
ccurred as a result of the treatment of a lower risk patient
ool, any mortality difference between hospital PCI volume
roups would have become smaller as the overall absolute
ortality rate decreased. Alternatively, data from California
ndicate that some smaller PCI volume hospitals stopped
roviding PCIs during the 1990s (24,25). The lack of a
ifference in this study in mortality rates between medium,
igh, and very high PCI volume hospitals may be because
edium-volume hospitals that stopped providing PCI were,
n average, hospitals with higher mortality rates. Finally,
ifferences in mortality between hospital PCI volume
roups may be both smaller and less well established than
ommonly acknowledged. A recent literature review noted
able 3. Hospital Annual PCI Volume and Odds of
n-Hospital Mortality
Hospital Annual PCI
Volume Groups
(Cases/Year Volume Cut Points) Unadjusted Adjusted*
ow (200) 1.58 (1.39–1.80) 1.21 (1.06–1.38)
edium (200–399) 1.12 (1.00–1.25) 1.02 (0.92–1.14)
igh (400–999) 1.00 (referent) 1.00 (referent)
ery high (1,000) 0.84 (0.76–0.93) 0.94 (0.85–1.03)
comparing medium and very
high volume hospitals
0.0001 0.16
comparing medium, high, very
high volume hospitals
0.0001 0.29
ow (200) 1.68 (1.47–1.90) 1.24 (1.09–1.41)
edium (200–399) 1.18 (1.06–1.32) 1.05 (0.95–1.16)
igh and very high (400) 1.00 (referent) 1.00 (referent)
ata are presented as odds ratios with 95% confidence intervals. *Analyses adjusted
or age, gender, race, payer, myocardial infarction, coronary artery disease, diabetes,
ypertension, chronic obstructive pulmonary disease, admission acuity, interhospital
ransfer, stent use, single versus multiple vessel procedure, and renal disease.
PCI  percutaneous coronary intervention.
igure 1. Box and whisker plot of hospitals’ standardized mortality ratios by
olume groups (1 low-volume, 2 medium-volume, 3 high-volume, 4
ortality ratio.hat nearly half of the published studies evaluating hospital
CI volume and outcomes had reported no association with
n-hospital mortality, while the remainder suggested only a
odest mortality difference (35).
We believe our findings have important implications
oncerning the use of hospital volume as a proxy for PCI
uality. Our findings, along with evidence of the benefits of
ospital competition (36), the economic consequences of
estricting PCI provision (37), and patients’ documented
illingness to tolerate increased mortality rates at local
ospitals rather than travel to lower mortality rate regional
ospitals for treatment (38) challenge the benefit of a
ospital PCI volume standard of 400 annual cases (4).
urther, the current PCI volume minimum criterion would
nfairly affect the majority of hospitals in the medium-
olume group with outcomes that are better than or com-
arable to what would be expected given their patient
ase-mix (i.e., SMR 1).
Our findings also underscore the importance of periodic
eevaluation of the volume-outcome association in order to
llow for changes in technology and practice patterns.
ecent data supporting the increased use of interventional
trategies in the management of unstable angina (39),
enefits provided by new pharmacologic therapies (40), and
he promise of drug-eluting stents (41) make it apparent
hat PCI practice is continuously evolving. This is consis-
ent with the pattern of decreasing differences in mortality
etween hospital PCI volume groups (24,26). Thus, the
uggestion that there is sufficient evidence to “move ahead”
ith existing volume standards (42) may, in the case of PCI,
e premature given the dated information upon which those
tandards are based. Future studies of the PCI volume-
utcome association will be needed to identify and test new
olume thresholds, and ultimately to determine the pro-
ess(es) through which volume and outcomes are linked.
There are four potential limitations of our evaluation that
erit specific consideration. First, our analysis used admin-
utaneous coronary intervention (PCI) volume groups. X-axis: hospital PCI
ry high-volume). Y-axis: standardized mortality ratio. smr standardizedperc
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May 19, 2004:1755–62 Hospital PCI Volumestrative data, and thus may not have captured the full
linical detail of a patient’s risk profile. However, it is
nclear whether having additional clinical data would have
ed us to uncover a meaningful difference in mortality
etween medium- and high-volume PCI hospitals. Given
hat patients treated at low- and medium-volume hospitals
ad a higher risk profile based on this administrative data, it
s likely that more detailed clinical risk adjustment would
ave further narrowed any putative hospital PCI volume-
ssociated mortality difference.
Second, we evaluated in-hospital mortality alone and
ould not assess other patient outcomes, including peripro-
edural complications, repeat revascularization rates, or
onger-term outcomes. However, current ACC/AHA PCI
linical practice guidelines recommend hospital PCI volume
inimums primarily on the basis of prior studies demon-
trating a reduction in procedure-related mortality (3).
imilarly, the Leapfrog Group explicitly justifies hospital
CI volume minimums as a means of reducing mortality
4). In addition, long-term outcomes are reportedly compa-
able for patients treated at different PCI volume hospitals,
uggesting that any differences in outcomes between PCI
olume hospitals are observed during hospitalization
22,43).
Third, the NIS does not track the experience of individ-
al physicians. Thus, we cannot account for the influence of
ndividual operator PCI volume on the association between
ospital PCI volume and mortality. Physician PCI volume
ay modify the association between hospital PCI volume
nd outcomes, particularly if physicians at low-volume
ospitals practice at more than one hospital. However, prior
tudies suggest both volume measures influence patient
utcomes independently (9,11,19), and current ACC/AHA
uidelines recommend separate operator and hospital an-
ual PCI volume minimums (3). More importantly, if
ndividual physician PCI volumes account primarily for the
ssociation between hospital PCI volume and outcomes,
hen efforts to reduce PCI mortality should focus on
perator, and not hospital, volume. In addition, patients
ndergoing PCI who did not require hospitalization would
ot be represented in our sample, although it is uncertain
hat proportion of patients are in this group and how they
re distributed across hospital PCI volume groups.
Finally, the NIS database does not contain unique patient
dentifiers. The inclusion of multiple patient admissions in
ur cohort may violate the statistical assumption of inde-
endence of observations. However, patient readmissions
ould alter our findings substantively only if readmissions
ere not randomly distributed across hospital PCI volume
roups, and if readmission constituted an independent
ortality risk beyond that measured by our current covari-
tes.
onclusions. Our evaluation of more than 360,000 PCIs
rom a national random sample of U.S. hospitals between
998 and 2000 found no difference in mortality rates for
atients treated at medium (200 to 399 cases/year), high400 to 999 cases/year), and very high (1,000 cases/year)
CI volume hospitals after accounting for differences in
ase-mix. Moreover, within each of the hospital PCI
olume groups, we detected substantial heterogeneity in
ospital mortality. These results contradict current ACC/
HA clinical practice guidelines recommending all hospi-
als perform 400 PCIs each year. Our findings also question
he usefulness of efforts by the Leapfrog Group to adopt
CI hospital volume minimums as a means of improving
uality of care. Future evaluations of hospital PCI volume
hresholds will be needed to assess recent and pending
hanges in PCI technology and practice.
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